IVA Logo

Inventiva S.A. (IVA) Stock Forecast & Price Prediction

Live IVA Stock Price & Analysis

Home โ€บ Stocks โ€บ France | NASDAQ | Healthcare | Biotechnology

$2.43

-0.10 (-3.80%)

12 Month Price Forecast For IVA

$2.43
Current Price
$222.56M
Market Cap
6 Ratings
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to IVA Price Forecasts

+722.0%
To High Target of $20.00
+413.8%
To Median Target of $12.50
+23.5%
To Low Target of $3.00

IVA Price Momentum

0.0%
1 Week Change
+9.5%
1 Month Change
-32.3%
1 Year Change
+13.6%
Year-to-Date Change
-45.9%
From 52W High of $4.50
+59.0%
From 52W Low of $1.53

๐Ÿค” Considering Inventiva (IVA)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 3:50 AM UTC

IVA Analyst Ratings & Price Targets

Based on our analysis of 7 Wall Street analysts, IVA has a consensus that is bullish. The median price target is $12.50, with forecasts ranging from $3.00 to $20.00. Currently, there are 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings.

With IVA currently trading at $2.43, the median price forecast suggests a 413.8% upside. The most optimistic forecast comes from Annabel Samimy at Stifel, projecting a 722.0% upside, while at provides the most conservative target, suggesting a 23.5% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

IVA Analyst Consensus

5
Buy
1
Hold
0
Sell

IVA Price Target Range

Low
$3.00
Average
$12.50
High
$20.00
Current: $2.43

Latest IVA Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for IVA.

Date Firm Analyst Rating Change Price Target
Jan 30, 2025 HC Wainwright & Co. Ed Arce Buy Reiterates $13.00
Nov 22, 2024 Stifel Annabel Samimy Buy Maintains $17.00
Nov 12, 2024 UBS Eliana Merle Neutral Initiates $3.00
Oct 15, 2024 HC Wainwright & Co. Ed Arce Buy Maintains $13.00
Sep 26, 2024 Stifel Annabel Samimy Buy Maintains $20.00
Sep 26, 2024 HC Wainwright & Co. Ed Arce Buy Maintains $14.00
Sep 26, 2024 HC Wainwright& Co. Buy Maintains $0.00
Apr 8, 2024 Canaccord Genuity Edward Nash Buy Maintains $20.00
Apr 1, 2024 HC Wainwright & Co. Ed Arce Buy Reiterates $22.00
Mar 20, 2024 HC Wainwright & Co. Ed Arce Buy Reiterates $22.00
Mar 8, 2024 HC Wainwright & Co. Ed Arce Buy Maintains $22.00
Feb 16, 2024 Stifel Annabel Samimy Buy Maintains $25.00
Dec 21, 2023 HC Wainwright & Co. Ed Arce Buy Maintains $24.00
Oct 27, 2023 Canaccord Genuity Edward Nash Buy Initiates $12.00
Sep 21, 2023 Roth MKM Dylan Dupuis Buy Reiterates $11.00
Sep 1, 2023 Guggenheim Etzer Darout Buy Reiterates $12.00
Jul 28, 2023 HC Wainwright & Co. Buy Reiterates $0.00
Jun 16, 2023 HC Wainwright & Co. Ed Arce Buy Reiterates $35.00
May 31, 2023 Roth MKM Dylan Dupuis Buy Initiates $11.00
May 26, 2023 HC Wainwright & Co. Ed Arce Buy Reiterates $35.00

Stocks Similar to Inventiva S.A.

The following stocks are similar to Inventiva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Inventiva S.A. (IVA) Financial Data

Inventiva S.A. has a market capitalization of $222.56M with a P/E ratio of -1.0x. The company generates $19.90M in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is -58.7% quarter-over-quarter, while maintaining an operating margin of -1,911.1% and return on equity of +344.7%.

Valuation Metrics

Market Cap $222.56M
Enterprise Value $202.04M
P/E Ratio -1.0x
PEG Ratio 0.0x
Price/Sales 11.5x

Growth & Margins

Revenue Growth (YoY) -58.7%
Gross Margin N/A
Operating Margin -1,911.1%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +8.2%
Current Ratio 0.6x
Debt/Equity -2.4x
ROE +344.7%
ROA -113.3%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Inventiva S.A. logo

Inventiva S.A. (IVA) Company Overview

About Inventiva S.A.

What They Do

Develops therapies for liver and rare diseases.

Business Model

Inventiva S.A. focuses on creating oral small molecule therapies targeting specific diseases, primarily non-alcoholic steatohepatitis (NASH) and rare genetic disorders. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapies once they receive regulatory approval.

Additional Information

Founded in 2011 and headquartered in Daix, France, Inventiva is currently advancing its lead product candidate, Lanifibranor, in Phase III clinical trials. The company also has a pipeline that includes Odiparcil for mucopolysaccharidosis type VI and various earlier-stage programs in oncology and other therapeutic areas.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

123

CEO

Mr. Frederic Cren

Country

France

IPO Year

2020

Inventiva S.A. (IVA) Latest News & Analysis

IVA stock latest news image
Quick Summary

Inventiva announced positive results from a clinical study on lanifibranor for treating type 2 diabetes and metabolic liver disease, showing significant improvements in insulin resistance.

Why It Matters

Positive clinical trial results for lanifibranor could enhance Inventiva's market position, potentially boosting stock value and attracting investor interest in the biopharmaceutical sector.

Source: GlobeNewsWire
Market Sentiment: Neutral
IVA stock latest news image
Quick Summary

Inventiva, a clinical-stage biopharmaceutical company, reported on its liquidity contract with Kepler Cheuvreux in its half-year update, focusing on therapies for metabolic dysfunction-related diseases.

Why It Matters

The liquidity contract report indicates Inventiva's financial health and market activity, which can influence stock performance and investor confidence in the company's future.

Source: GlobeNewsWire
Market Sentiment: Neutral
IVA stock latest news image
Quick Summary

Inventiva will present Proof-of-Concept trial results for lanifibranor and empagliflozin in treating MASH at the SLD Summit 2025, hosted by EASL from January 23-25 in Portugal.

Why It Matters

The presentation of positive trial results at a major medical conference can boost Inventiva's credibility and attract investor interest, potentially impacting stock performance and partnerships.

Source: GlobeNewsWire
Market Sentiment: Neutral
IVA stock latest news image
Quick Summary

Inventiva announced it will issue โ‚ฌ21.4 million in the second phase of its multi-tranche equity financing, totaling up to โ‚ฌ348 million, to support its biopharmaceutical development.

Why It Matters

The announcement of a โ‚ฌ21.4 million capital raise indicates strong investor interest and funding for Inventiva's clinical projects, potentially enhancing growth prospects and stock value.

Source: GlobeNewsWire
Market Sentiment: Neutral
IVA stock latest news image
Quick Summary

Inventiva (IVA), a biopharmaceutical firm focused on treatments for NASH, will present at the J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco.

Why It Matters

Inventiva's presentation at a major healthcare conference highlights its focus on a significant market (NASH) and potential investor interest, impacting stock performance and market perception.

Source: GlobeNewsWire
Market Sentiment: Neutral
IVA stock latest news image
Quick Summary

Inventiva announced the results of its Combined Shareholders' Meeting on December 11, 2024. The company focuses on developing therapies for MASH/NASH and other unmet medical needs.

Why It Matters

The outcome of the shareholders' meeting could impact company strategy and future funding, influencing Inventiva's stock performance and investor sentiment in the biopharmaceutical sector.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About IVA Stock

What is Inventiva S.A.'s (IVA) stock forecast for 2025?

Based on our analysis of 7 Wall Street analysts, Inventiva S.A. (IVA) has a median price target of $12.50. The highest price target is $20.00 and the lowest is $3.00.

Is IVA stock a good investment in 2025?

According to current analyst ratings, IVA has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.43. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for IVA stock?

Wall Street analysts predict IVA stock could reach $12.50 in the next 12 months. This represents a 413.8% increase from the current price of $2.43. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Inventiva S.A.'s business model?

Inventiva S.A. focuses on creating oral small molecule therapies targeting specific diseases, primarily non-alcoholic steatohepatitis (NASH) and rare genetic disorders. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapies once they receive regulatory approval.

What is the highest forecasted price for IVA Inventiva S.A.?

The highest price target for IVA is $20.00 from Annabel Samimy at Stifel, which represents a 722.0% increase from the current price of $2.43.

What is the lowest forecasted price for IVA Inventiva S.A.?

The lowest price target for IVA is $3.00 from at , which represents a 23.5% increase from the current price of $2.43.

What is the overall IVA consensus from analysts for Inventiva S.A.?

The overall analyst consensus for IVA is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $12.50.

How accurate are IVA stock price projections?

Stock price projections, including those for Inventiva S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.